Search

Your search keyword '"Gallagher, Geneviève"' showing total 16 results
Start Over Author "Gallagher, Geneviève"
16 results on '"Gallagher, Geneviève"'

1. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial

Author

Walker, Irwin, Panzarella, Tony, Couban, Stephen, Couture, Felix, Devins, Gerald, Elemary, Mohamed, Gallagher, Geneviève, Kerr, Holly, Kuruvilla, John, Lee, Stephanie J, Moore, John, Nevill, Thomas, Popradi, Gizelle, Roy, Jean, Schultz, Kirk R, Szwajcer, David, Toze, Cynthia, and Foley, Ronan

Published
2020
Full Text
View/download PDF

4. Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells

Author

Kariminia, Amina, Holtan, Shernan G., Ivison, Sabine, Rozmus, Jacob, Hebert, Marie-Josée, Martin, Paul J., Lee, Stephanie J., Wolff, Daniel, Subrt, Peter, Abdossamadi, Sayeh, Sung, Susanna, Storek, Jan, Levings, Megan, Aljurf, Mahmoud, Arora, Mukta, Cutler, Corey, Gallagher, Geneviève, Kuruvilla, John, Lipton, Jeff, Nevill, Thomas J., Newell, Laura F., Panzarella, Tony, Pidala, Joseph, Popradi, Gizelle, Szwajcer, David, Tay, Jason, Toze, Cynthia L., Walker, Irwin, Couban, Stephen, Storer, Barry E., and Schultz, Kirk R.

Published
2016
Full Text
View/download PDF

5. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial

Author

Walker, Irwin, Panzarella, Tony, Couban, Stephen, Couture, Felix, Devins, Gerald, Elemary, Mohamed, Gallagher, Geneviève, Kerr, Holly, Kuruvilla, John, Lee, Stephanie J, Moore, John, Nevill, Thomas, Popradi, Gizelle, Roy, Jean, Schultz, Kirk R, Szwajcer, David, Toze, Cynthia, and Foley, Ronan

Published
2016
Full Text
View/download PDF

6. Population Snapshot of Emergent Streptococcus pneumoniae Serotype 19A in the United States, 2005

Author

Moore, Matthew R., Gertz,, Robert E., Woodbury, Robyn L., Barkocy-Gallagher, Genevieve A., Schaffner, William, Lexau, Catherine, Gershman, Kenneth, Reingold, Arthur, Farley, Monica, Harrison, Lee H., Hadler, James L., Bennett, Nancy M., Thomas, Ann R., McGee, Lesley, Pilishvili, Tamara, Brueggemann, Angela B., Whitney, Cynthia G., Jorgensen, James H., and Beall, Bernard

Published
2008
Full Text
View/download PDF

9. Anti-Thymocyte Globulin for Patients Undergoing Hematopoietic Cell Transplantation from Unrelated Donors: A Randomized, Controlled, Open-Label, Phase 3, Multicentre Trial from Cell Therapy Transplant Canada

Author

Walker, Irwin, primary, Panzarella, Tony, additional, Couban, Stephen, additional, Couture, Felix, additional, Devins, Gerald, additional, Elemary, Mohamed, additional, Gallagher, Geneviève, additional, Kerr, Holly, additional, Kuruvilla, John, additional, Lee, Stephanie, additional, Moore, John, additional, Nevill, Thomas, additional, Popradi, Gizelle, additional, Roy, Jean, additional, Schultz, Kirk R., additional, Szwajcer, David, additional, Toze, Cynthia, additional, and Foley, Ronan, additional

Published
2019
Full Text
View/download PDF

13. Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+NK cells

Author

Kariminia, Amina, Holtan, Shernan G., Ivison, Sabine, Rozmus, Jacob, Hebert, Marie-Josée, Martin, Paul J., Lee, Stephanie J., Wolff, Daniel, Subrt, Peter, Abdossamadi, Sayeh, Sung, Susanna, Storek, Jan, Levings, Megan, Aljurf, Mahmoud, Arora, Mukta, Cutler, Corey, Gallagher, Geneviève, Kuruvilla, John, Lipton, Jeff, Nevill, Thomas J., Newell, Laura F., Panzarella, Tony, Pidala, Joseph, Popradi, Gizelle, Szwajcer, David, Tay, Jason, Toze, Cynthia L., Walker, Irwin, Couban, Stephen, Storer, Barry E., and Schultz, Kirk R.

Abstract

Chronic graft-versus-host disease (cGVHD) remains one of the most significant long-term complications after allogeneic blood and marrow transplantation. Diagnostic biomarkers for cGVHD are needed for early diagnosis and may guide identification of prognostic markers. No cGVHD biomarker has yet been validated for use in clinical practice. We evaluated both previously known markers and performed discovery-based analysis for cGVHD biomarkers in a 2 independent test sets (total of 36 cases ≤1 month from diagnosis and 31 time-matched controls with no cGVHD). On the basis of these results, 11 markers were selected and evaluated in 2 independent replication cohorts (total of 134 cGVHD cases and 154 controls). cGVHD cases and controls were evaluated for several clinical covariates, and their impact on biomarkers was identified by univariate analysis. The 2 replications sets were relatively disparate in the biomarkers they replicated. Only sBAFF and, most consistently, CXCL10 were identified as significant in both replication sets. Other markers identified as significant in only 1 replication set included intercellular adhesion molecule 1 (ICAM-1), anti-LG3, aminopeptidase N, CXCL9, endothelin-1, and gelsolin. Multivariate analysis found that all covariates evaluated affected interpretation of the biomarkers. CXCL10 had an increased significance in combination with anti-LG3 and CXCL9, or inversely with CXCR3+CD56brightnatural killer (NK) cells. There was significant heterogeneity of cGVHD biomarkers in a large comprehensive evaluation of cGVHD biomarkers impacted by several covariates. Only CXCL10 strongly correlated in both replication sets. Future analyses for plasma cGVHD biomarkers will need to be performed on very large patient groups with consideration of multiple covariates.

Published
2016
Full Text
View/download PDF

14. Outcomes of adults with refractory or relapsed acute myeloid leukemia treated with azacitidine and venetoclax compared to other therapies: a multicenter retrospective study.

Author

Pelland, Andrée-Anne, Deschênes-Simard, Xavier, Savard, Xavier, Giguère, Philippe, Spillane, David, Barabé, Frédéric, Laroche, Vincent, Munger, Michaël, Gallagher, Geneviève, Marcoux, Nicolas, Cantin, Guy, Chénard-Poirier, Maxime, Delage, Robert, Lalancette, Marc, Veilleux, Olivier, Assouline, Sarit E., and Lemieux, Christopher

Subjects
*ACUTE myeloid leukemia, *SALVAGE therapy, *SEPTIC shock, *INTENSIVE care units, *VENETOCLAX, *STEM cell transplantation, *FEBRILE neutropenia
Abstract

AbstractThis study reports characteristics and outcomes of adults who received Azacitidine-Venetoclax (AZA-VEN) compared to other salvage therapies (NO-AZA-VEN) as first salvage therapy for acute myeloid leukemia (AML). The clinical data of 81 patients with a diagnosis of relapsed or refractory AML were analyzed. The ORR was comparable for both groups (55% vs 57%, p = 0.852). Median OS (6.8 vs 11.2 months, p = 0.053) and median RFS (6.9 vs 11.2 months, p = 0.488) showed a trend in favor of the NO-AZA-VEN group. OS was significantly longer with NO-AZA-VEN for ELN 2022 risk category sub-group, patients under 60 years old, primary AML and for patients who underwent allo-hematopoietic stem cell transplant after salvage therapy. There was no statistical difference in complications of treatment such as febrile neutropenia, intensive care unit stay, septic shock and total parenteral nutrition. Those results do not support the preferential use of AZA-VEN over other regimens in R/R acute myeloid leukemia. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells.

Author

Kariminia, Amina, Holtan, Shernan G., Ivison, Sabine, Rozmus, Jacob, Hebert, Marie-Josée, Martin, Paul J., Lee, Stephanie J., Wolff, Daniel, Subrt, Peter, Abdossamadi, Sayeh, Sung, Susanna, Storek, Jan, Levings, Megan, Aljurf, Mahmoud, Arora, Mukta, Cutler, Corey, Gallagher, Geneviève, Kuruvilla, John, Lipton, Jeff, and Nevill, Thomas J.

Subjects
*GRAFT versus host disease, *BONE marrow transplant complications, *BIOMARKERS, *PROGNOSIS, *CD54 antigen
Abstract

Chronic graft-versus-host disease(cGVHD) remains one of the most significant long-term complications after allogeneic blood and marrow transplantation. Diagnostic biomarkers for cGVHD are needed for early diagnosis and may guide identification of prognostic markers. No cGVHD biomarker has yet been validated for use in clinical practice. We evaluated both previously known markers and performed discovery-based analysis for cGVHD biomarkers in a 2 independent test sets (total of 36 cases ≤1 month from diagnosis and 31 time-matched controls with no cGVHD). On the basis of these results, 11 markers were selected and evaluated in 2 independent replication cohorts (total of 134 cGVHD cases and 154 controls). cGVHD cases and controls were evaluated for several clinical covariates, and their impact on biomarkers was identified by univariate analysis. The 2 replications sets were relatively disparate in the biomarkers they replicated. Only sBAFF and, most consistently, CXCL10 were identified as significant in both replication sets. Other markers identified as significant in only 1 replication set included intercellular adhesion molecule 1 (ICAM-1), anti-LG3, aminopeptidase N, CXCL9, endothelin-1, and gelsolin. Multivariate analysis found that all covariates evaluated affected interpretation of the biomarkers. CXCL10 had an increased significance in combination with anti-LG3 andCXCL9,or inversely withCXCR31CD56bright natural killer (NK) cells. There was significant heterogeneity of cGVHD biomarkers in a large comprehensive evaluation of cGVHD biomarkers impacted by several covariates. Only CXCL10 strongly correlated in both replication sets. Future analyses for plasma cGVHD biomarkers will need to be performed on very large patient groups with consideration of multiple covariates. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results